Sotigalimab/Pembrolizumab Jumpstarts Immune Activity, Ignites Clinical Responses in Metastatic Melanoma

Source: Oncology Nursing News, April 2022

Treatment with the CD40 agonist sotigalimab (APX005M) in addition to pembrolizumab (Keytruda) elicited immunologic changes that yielded positive clinical responses in patients with unresectable stage III or IV metastatic melanoma, according to phase 1/2 findings (NCT02706353) presented during the 2022 AACR Annual Meeting.

Furthermore, the agent was found to have a favorable safety profile. Investigators also identified broad immune activity in both local and distant lesions through biomarker analysis.

In addition to evaluating the safety of sotigalimab, investigators determined the maximum-tolerated dose, the recommended phase 2 dose (RP2D), and objective response rate (ORR).